Recently our laboratory reported an intricate regulation of the human reduced folate carrier (hRFC) gene, involving multiple promoters and non-coding exons. We localized promoter activity to a 452 bp GC-rich region upstream of non-coding exon A, including a 47 bp basal promoter with a CRE/AP-1-like consensus element that bound the bZip family of DNA binding proteins (e. g., Creb-1and cJun). We now report that 
cJun, Creb-1, and ATF-1, to a CRE/AP1-like element in the minimal promoter (29) .
Most recently, we reported that the frequent use of promoter B in malignant tissues was associated with its regulation by multiple transcription factors, including oncogenic proteins such as cMyc and Ikaros, and by histone acetylation (30) 2 . Accordingly, celland tissue-specific usage of alternate hRFC promoters/non-coding exons could serve to regulate relative expression and function of hRFC in response to differences in folate levels within tissues, intracellular distributions of transcription factors, or epigenetic events. It is this complexity of controls that likely ensures adequate levels of hRFC transcripts (and protein) in response to metabolic requirements for folates, or other tissueor cell-specific signals.
In this report, we expand our initial analysis of hRFC-A, a major promoter in liver, bone marrow, and immortalized cell lines (19) , as well as in primary malignant cells 2 . Our results demonstrate that AP2 and Sp1 binding to a series of unique tandem nucleotide repeats in the hRFC-A upstream region is critical to promoter transactivation.
Moreover, we document the presence of a high frequency polymorphism in the repeated region, involving the insertion of an additional 61 nucleotides that influence hRFC-A transcriptional activity. This is the first report of a functional polymorphism in the hRFC gene that may contribute to interpatient variations in hRFC expression and response to antifolate cancer chemotherapeutics.
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Materials and Methods.
Chemicals and Reagents--[γ- 32 hRFC-Luciferase Reporter Constructs--The full length hRFC-A/-903 promoter construc t (positions -903 to -277) was previously described by Zhang et al. (31) . The promoter A construct with the additional 61 nucleotide repeat inserted between positions -715 and -714 (hRFC/Repeat 1 +) was previously described by Whetstine and Matherly (29) .
Specific DNA binding sites in promoter A were mutated by both standard PCR and "Soeing" PCR (32) , using the GC-Rich Kit (Roche) with Tgo polymerase (Roche).
The hRFC-A/-903 construct was used as a template. The hRFC-A /-903 mE construct, containing the mutated E-box, was prepared by a standard PCR reaction using the - "Soeing" PCR was used to mutate specific elements in promoter A using the primers shown in Gel Mobility Shift Assays--Gel shift assays were performed exactly as previously described (29) . Twelve µg of HT1080 nuclear extract was used in each binding reaction.
The 
Results.
In vitro binding of USF-1, AP2, and Mzf-1 to the hRFC-A promoter. Our previous studies of the regulation of the hRFC gene confirmed that promoter activity was associated with a 452 bp GC-rich region immediately upstream from exon A that was devoid of a TATA-box but contained a number of putative transcription elements (31).
The basal hRFC-A promoter was localized to within 47 bp (positions -501 to -455; see The identities of the DNA/protein complexes were further assessed on gel shifts with end-labeled hRFC-A/R1 oligonucleotides with mutations in the potential AP2 (2) and/or Mzf-1(2) sites (lanes [12] [13] [14] . Thus, mutation of the AP2 (2) 
Mutagenesis of transcription factor binding elements in the hRFC-A upstream region.
To further assess the importance of the major binding sites identified in the hRFC-A upstream region by in vitro binding assays, the individual elements were mutated. The mutant hRFC-A promoter constructs in pGL3 Basic vector were transiently transfected into HT1080 cells, and luciferase activities were compared to that of the wildtype hRFC-A/-903 construct. When the Mzf-1(1), E-box, Mzf-1(2), and GC-box(1) sites (Figure 1) were individually mutated, insignificant changes in promoter A activity were observed (<10%; p>0.05). However, the effects of other individual mutations were significant (p<0.05) and ranged from a 23% (± 5%) [for AP2 (1) ] or 25% (± 3%) [for AP2 (2)] increase in promoter activity to a 37% (± 6%) decrease in activity [GC-Box (2)].
Interestingly, when both the AP2(2) and Mzf-1(2) elements were mutated, a striking 37%
(± 5%) decrease in promoter activity was observed, consistent with our gel shift findings ( Figure 2B ) that imply a functional interaction between AP2 and Mzf-1-like factors bound to these sites. Collectively, our mutation results suggest that the AP2[ (1) and (2)], Mzf-1(2), and GC-box(2) binding sites are important for promoter A activity. Figure 4A ). The long isoform of Sp3 (but not the short Sp3 isoforms) was also able to activate promoter A, although it was less effective than Sp1 (~6-fold; data not shown). When GC-box (2) was mutated [Repeat 3 mGC (2)], the net stimulation by Sp1 was decreased by 55%, however, there was no significant effect of mutating GC-box ( To evaluate whether this insertion is a mutation or a polymorphism, gDNAs from 72 normal (non-disease) patients were amplified and analyzed on agarose gels as seen in Figure 5A . Surprisingly, 43 (63%) of the specimens were homozygous for the 722 bp 
Cotransfections of Promoter
Discussion.
We previously localized the minimal hRFC-A promoter to within 47 bp, including a CRE/AP-1-like element that bound the bZip family of transcription factors (e.g., Creb-1, ATF-1, and cJun) (29) . In this report, we characterize the role of the hRFC-A upstream region, which includes a novel series of tandem nucleotide repeats, and describe a polymorphic 61 bp insertion in the repeated region. Although Sp1 had no effect on transcription from the 47 bp hRFC-A minimal hRFC-A promoter (29) , this factor markedly stimulated activity for the full length hRFC-A construct and synergized with Creb-1. Interestingly, these effects on promoter activity were specific to Sp1 since the long isoform of Sp3 was less effective and failed to synergize with Creb-1, and the short Sp3 isoforms were completely inert. However In this report, we identify the first functional polymorphism for hRFC. We originally reported that the hRFC-A promoter contained three tandem repeated sequences and Sp3 (lane 9). For panels A-C, the complexes for each gel shift probe are labeled with letters and arrowheads and the supershifted complexes are marked with arrows. The nonspecific band is noted with a cross. Gel shifted complexes were resolved on a 5% nondenaturing gel, and DNase I footprints were resolved on a denaturing 8% gel. Figure 4 by guest on 
